PlainPharmaWatch

CMS Open Payments · Program Year 2024

Medinc of Texas

Medinc of Texas reported $86,521.43 across General Payments, Research, and Ownership to 1,048 physicians and teaching hospitals across 1,048 transactions.

$86.5K
All-tracks total
1,048
Transactions
1,048
Recipients
+$12.6K
General Payments vs PY2023

Medinc of Texas reported $86,521.43 across all CMS Open Payments tracks (General + Research + Ownership) to 1,048 physicians and teaching hospitals in Program Year 2024 - ranking #1220 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $86,521.43, averaging $82.56 per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

CMS Sunshine Act warrant

Manufacturer medinc-of-texas Medinc of Texas

$86.5K · #1220/1,925 · 0.0% industry · PY2024

  • TOT $86.5K
  • RANK #1220
  • SHARE 0.0%
  • TXN 1,048
  • RCP 1,048
  • CAT 2
  • GEN $86.5K
  • ΔGEN +$12.6K
  • TOP1 3.9%
  • PY 2024

Nearest volume peer: Huntleigh Healthcare Ltd. ($86.6K)

180 Medical, Inc.$86.9KHuntleigh Healthcare Ltd.$86.6KMedinc of Texas (this)$86.5KOtter Pharmaceuticals, LLC$86.2KRichard Wolf Medical Instrum…$85.7K
All-tracks payment totals near Medinc of Texas (CMS Open Payments PY2024)

Medinc of Texas sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Medinc of Texas's CMS-reported General Payments increased by $12.6K (+17.0%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: MEDINC OF TEXASPY2023: MEDINC OF TEXASPY2024: Medinc of Texas. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$73.9KPY2024$86.5K
PY2023
$73,947.02
PY2024
$86,521.43

What the Data Shows for Medinc of Texas

Rank #1220 of 1,925 companies in CMS Open Payments for 2024 belongs to Medinc of Texas, which reported $86,521.43 across 1,048 transactions to 1,048 recipients - a comparatively small 0.0% slice of all industry payments reported nationwide for the year. Averages work out to $82.56 per transaction and $82.56 per recipient.

The 2-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Food and Beverage" at $57.1K, accounting for 66.0% of this company's General Payments and 936 transactions.

General Payment Breakdown by Type

"Food and Beverage" leads Medinc of Texas's 2-category general-payment breakdown at $57.1K, 66.0% of the reported total.

How Medinc of Texas divides its payments

Top payment categories by total reported dollar volume

1. Food and Beverage$57.1K2. Travel and Lodging$29.4K
Payment Type Amount Transactions
Food and Beverage $57.1K 936
Travel and Lodging $29.4K 112

Recipient Concentration in General Payments

The five largest recipient relationships account for $10,955.08 (12.7%) of $86,521.43 in this company's General Payments records across 448 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Medinc of Texas

The five named recipients with the highest reported General Payments from this company

Matthew Weldon$3.3KJohn Munz$2.3KLisa Degarmo$1.9KRabah Qadir$1.7KViacheslav Bobovnikov$1.7K
  1. 1

    Matthew Weldon

    $3,346.51 across 25 reported transactions

  2. 2

    John Munz

    $2,330.76 across 36 reported transactions

  3. 3

    Lisa Degarmo

    $1,943.38 across 13 reported transactions

  4. 4

    Rabah Qadir

    $1,678.65 across 27 reported transactions

  5. 5

    Viacheslav Bobovnikov

    $1,655.78 across 13 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Medinc of Texas's, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Medinc of Texas.

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Medinc of Texas.

Showing 6 of 1,924 companies with CMS-reported payment data.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

View saved (companies)
Download Medinc of Texas's data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.